PEPTIDE

Cagrilintide

Long-acting amylin analog; suppresses appetite and gastric emptying. In Phase 3 as CagriSema combination with semaglutide.

BIOGATE · GREEN | POSTERIOR 39.3% | MW 3890.4 | 37AA

SEQUENCE

KCNTATCATNRLANFLVRSSNNLGPVLPPTNVGSNTY

Modifications: disulfide C2-C7; ℇGlu-C18 lipid sidechain; amidated C-terminus

PDA-V1 chain of custody

Outer hash

`dd1a2a61dc1a28cedb1a273bda1a25a8e11a30ade01a2f1adf1a2d8`

Merkle root

`f39c3254f49c33e7f59c357af69c370def9c2c08f09c2d9bf19c2f2ef29c30c1`

Inputs

`13-d1fae112d1f94e11d1f7bb10d1f62817d2012d16d1ff9a15d1fe071`

TEE attestation

`13-a98b6e14a98d0111a9884812a989db17a991ba18a9934d15a98e9416a99027`

Living Outcome Oracle

± =35.1 ² =54.2 **P(success) = 39.3%** 95% CI [27.3%, 51.3%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A — 2021 · Lancet

Once-weekly cagrilintide for weight management in people with overweight and obesity

Lau DCW et al.

PMID 34672969